Single patient gets expanded access to experimental GVHD drug
NCT ID NCT05544032
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This program provides expanded access to axatilimab for one patient with chronic graft versus host disease (GVHD), a condition where donor immune cells attack the patient's body after a stem cell transplant. The treatment aims to control the disease, but patients typically need ongoing medication. Approval is required from the company, ethics committee, and the FDA.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VS. HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.